Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
17/04/2012
17/04/2012
2008
|
Resumo |
Background: Thyroid receptors, TRa and TR beta, are involved in important physiological functions such as metabolism, cholesterol level and heart activities. Whereas metabolism increase and cholesterol level lowering could be achieved by TR beta isoform activation, TRa activation affects heart rates. Therefore, beta-selective thyromimetics have been developed as promising drug-candidates for treatment of obesity and elevated cholesterol level. GC-1 [ 3,5-dimethyl-4-(4'-hydroxy- 3'-isopropylbenzyl)-phenoxy acetic acid] has ability to lower LDL cholesterol with 600-to 1400-fold more potency and approximately two-to threefold more efficacy than atorvastatin (Lipitor(C)) in studies in rats, mice and monkeys. Results: To investigate GC-1 specificity, we solved crystal structures and performed molecular dynamics simulations of both isoforms complexed with GC-1. Crystal structures reveal that, in TRa Arg228 is observed in multiple conformations, an effect triggered by the differences in the interactions between GC-1 and Ser277 or the corresponding asparagine (Asn331) of TR beta. The corresponding Arg282 of TR beta is observed in only one single stable conformation, interacting effectively with the ligand. Molecular dynamics support this model: our simulations show that the multiple conformations can be observed for the Arg228 in TR alpha, in which the ligand interacts either strongly with the ligand or with the Ser277 residue. In contrast, a single stable Arg282 conformation is observed for TR beta, in which it strongly interacts with both GC-1 and the Asn331. Conclusion: Our analysis suggests that the key factors for GC-1 selectivity are the presence of an oxyacetic acid ester oxygen and the absence of the amino group relative to T(3). These results shed light into the beta-selectivity of GC-1 and may assist the development of new compounds with potential as drug candidates to the treatment of hypercholesterolemia and obesity. Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, grants #06/00182-8) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, grants #479800/2004-9 to MSS and #473875/2003-9 to IP) Coordenação de Aperfeiçoamento de Pessoal do Nível Superior (CAPES) National Institutes of Health (DK41482 and DK64148 to JDB) |
Identificador |
BMC STRUCTURAL BIOLOGY, v.8, 2008 1471-2237 http://producao.usp.br/handle/BDPI/14949 10.1186/1472-6807-8-8 |
Idioma(s) |
eng |
Publicador |
BIOMED CENTRAL LTD |
Relação |
BMC Structural Biology |
Direitos |
openAccess Copyright BIOMED CENTRAL LTD |
Palavras-Chave | #MOLECULAR-DYNAMICS SIMULATIONS #X-RAY-DIFFRACTION #AGONIST GC-1 #LIGAND DISSOCIATION #GENE SUPERFAMILY #SERUM-LIPIDS #TR-BETA #CHOLESTEROL #MICE #TRIIODOTHYRONINE #Biophysics |
Tipo |
article original article publishedVersion |